WEBULL

MedinCell (ENXTPA:MEDCL) Secures €28 Million In Loans, Is The Discount Too Wide?

Simply Wall St · 1d ago

MedinCell (ENXTPA:MEDCL) drew investor attention after securing €28 million in non dilutive bank loans from European lenders, extending debt maturities to mid 2031 and planning early repayment of part of its EIB facility.

See our latest analysis for MedinCell.

These financing moves come after a period of strong momentum for MedinCell, with a 90 day share price return of 13.74% and a 1 year total shareholder return of 50.72%, while the 3 year total shareholder return is more than 3 times the initial investment.

If you are weighing MedinCell alongside other opportunities in healthcare, it can be useful to see how the market is pricing growth in AI driven treatments through our screener of 129 healthcare AI stocks

MedinCell now trades at a sizeable discount to both analyst targets and an estimated intrinsic value, despite its fresh €28 million financing and extended debt runway. Is the market’s caution reflecting risk or mispricing?

Most Popular Narrative: 25.9% Undervalued

The most followed narrative on MedinCell pegs fair value at €35.07 per share, compared with the last close of €26.00, and builds its case around the long acting injectable pipeline and partnership model.

MedinCell's financial performance is currently reliant on the successful commercialization and continued growth of just two products, UZEDY and Olanzapine LAI, making it vulnerable to clinical, regulatory, or competitive setbacks in either, and any delays or failures would significantly impact future revenue and net earnings.

Read the complete narrative.

Want to see what justifies that gap between price and fair value? The narrative leans on brisk revenue expansion, a sharp profit swing, and a premium earnings multiple. Curious how those moving parts fit together in the model?

Result: Fair Value of €35.07 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the MedinCell narrative still leans heavily on successful execution for UZEDY and Olanzapine LAI, and on continued access to funding for its broader pipeline.

Find out about the key risks to this MedinCell narrative.

Another View on MedinCell’s Valuation

The earlier narrative leans on discounted future cash flows to argue MedinCell looks significantly undervalued. A different lens is the current P/S of 38.5x, compared with a fair ratio of 9.2x, 18.2x for peers and 3.9x for the wider European pharmaceuticals group. That kind of premium signals real valuation risk if sentiment shifts, so which signal do you trust more?

See what the numbers say about this price — find out in our valuation breakdown.

ENXTPA:MEDCL P/S Ratio as at Jul 2026
ENXTPA:MEDCL P/S Ratio as at Jul 2026

Next Steps

Mixed signals around MedinCell’s valuation and risk profile make this a stock where you benefit from looking at the details yourself rather than the headlines. If you want a concise view of what current investors see on both sides of the argument, take a moment to review the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond MedinCell?

If MedinCell has sharpened your interest in healthcare and high conviction stories, do not stop here when there are other focused sets of stocks worth your attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.